News
News Releases
Altesa Biosciences To Initiate Clinical Trials Of Promising Antiviral
CEO Giroir announces Altesa’s IND for vapendavir has the FDA green light for clinical study at AdvanSE Conference ATLANTA – May 26, 2022 – Altesa BioSciences, Inc. (Altesa), a clinical-stage biopharmaceutical company developing and commercializing novel antiviral...
Altesa Biosciences Recognizes Co-Founder and Partner for Major NIH Research Grant to Discover New Antiviral Drugs
George Painter, Emory Professor and CEO of DRIVE, awarded $52 million to co-lead Antiviral Countermeasures Development Center ATLANTA, May 25, 2022 – Altesa BioSciences, Inc., a clinical-stage biopharmaceutical company developing and commercializing novel antiviral...
Altesa BioSciences, Inc., Launches Operations to Develop, Commercialize Drugs for Respiratory Viruses and Global Viral Threats
https://altesabio.com/wp-content/uploads/2022/02/NR_ALTESA_LAUNCHES_OPS_02.10.2022.pdf
Vaxart Announces Exclusive Worldwide License Agreement with Altesa
https://investors.vaxart.com/news-releases/news-release-details/vaxart-announces-exclusive-worldwide-license-agreement-altesa
Media Coverage
Wall Street Journal
Altesa Bioscience Inc. has raised seed financing to develop drugs for viral diseases.
BioWorld
Hard DRIVE for virus fixes: Altesa, Emory take on global threats.
FIERCE Biotech
Ex-FDA interim chief Giroir rejoins biotech world with eyes on $50M fundraising for new infectious disease company.